Clinical Trial Update: An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy [Phase 2]

View source ↗

Summary

Open-label Bayesian adaptive Phase II clinical study in HR+/HER2- advanced breast cancer after progression on standard therapy; sponsored by Fudan University an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING